The firm saw strong growth in respiratory illness assays and lead testing, which was offset by a decline in C. difficile testing.
Palmetto GBA's decision that large syndromic MDx panels may not always be necessary prompted GenePOC's decision to further target smaller panels.
The test, which runs on the firm's Revogene molecular diagnostics instrument, has now been launched in Canada.
Meridian's diagnostics revenues grew 1 percent year over year to $36.4 million while its life science revenues jumped 8 percent to $15.4 million.
The platform counts single target molecules in stool samples within 30 minutes and without sample preparation to detect C. diff. toxins.
The firm expects to build out a menu for the reader, which will automate results reporting for colorimetric- and fluorescence-based tests.
The system will perform 200 multiplexed pathogen ID tests or 40 AST tests in one eight-hour shift on a random access, fully automated benchtop instrument.
Luminex was bullish about its molecular diagnostics business, Natera outlined its work with pharmaceutical firms, and Oxford discussed its plans in TB and tick-borne diseases.
Microgenics, Astute Medical, and Siemens were among the firms whose tests and/or systems were cleared by the FDA for marketing last month.
The Québec-based firm launched the test, which detects the toxin B gene of toxigenic C. diff strains directly from stool samples, in the US today.